OUR PLATFORM

Innate repair receptor (IRR) activation is the basis for a library of novel peptides targeting chronic and acute diseases

OUR CLINICAL FOCUS

The lead indications for our first-in-class compound, ARA 290, are neuropathy (sarcoid, diabetes) and other diabetes complications

Learn More
Learn More

Araim Pharmaceuticals Inc. is a clinical-stage drug development company with a novel platform technology designed to address devastating injuries and chronic diseases underserved by current therapies. With our discovery of the innate repair receptor (IRR), Araim has identified the target for activating tissue repair and recovery from inflammatory and other injuries. Our lead compound, ARA 290, a novel 11-amino-acid peptide, stimulates tissue protective, reparative, and

anti-inflammatory signaling pathways through selective IRR activation. Araim has an ongoing, active, and promising preclinical program in a wide array of conditions involving tissue injury and repair, including neuropathy, cardiovascular injury, diabetes complications, wound healing, and aging. ARA 290 has been granted US and EU orphan drug designations in several therapeutic areas, as well as US fast track status, and is in clinical-stage development for neuropathic and retinal diseases.